Coronary disease & ACSRandomised controlled trial
Vericiguat for the Treatment of Coronary Vasospasm (ViVA)
- Randomised controlled trial
- double-blind
- placebo-controlled
- crossover
Authors' conclusion
The ViVA (Vericiguat in Vasospastic Angina) trial did not demonstrate evidence of improved peripheral vasodilator function or anginal symptoms in patients with coronary vasospasm.
Study context
- Population
- Angina with nonobstructive coronary arteries (ANOCA) patients with epicardial and/or microvascular vasospasmcrossover
- Participants
- 57 patients
- Comparison
- Vericiguat vs placebo
- Primary endpoint
- Peripheral vasodilator function during acetylcholine iontophoresis (laser speckle contrast analysis); daily angina episodes via the ORBITA-app
Primary result
As reported in the abstract
Vericiguat vs PlaceboOdds ratio (95% CI)
final-day OR for reduction in angina episodes; posterior probability of benefit 0.07
0.84(0.65–1.04)
- peripheral vasodilator function, AUC
- intervention effect estimate −1,221 arbitrary perfusion units•seconds (95% CI −4,237 to 1,796); P = 0.42
Further findings
Episode counts and angina-free days · 70 days
- Similar between arms
Safety
Tolerability
- Treatment-related serious adverse events
- 0
- Modest reductions in BP; no clinically relevant laboratory abnormalities
Original publication
Vericiguat for the Treatment of Coronary Vasospasm (ViVA). J Am Coll Cardiol. Published 28 August 2026. doi:10.1016/j.jacc.2026.08.037
Summarised from the published abstract; every number is checked against it